Chronic hepatitis C healed by peginterferon-α and rivabirin treatment after kidney transplantation.
10.12701/yujm.2016.33.2.150
- Author:
Min Gue SEOK
1
;
Tae Hee LEE
;
Sung Ro YUN
;
Won Min HWANG
;
Se Hee YOON
;
In Soo CHOE
;
Seong Joo KANG
;
Ju Young HONG
;
Dae Sung KIM
Author Information
1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea. green740@naver.com
- Publication Type:Case Report
- Keywords:
Kidney transplantation;
Chronic hepatitis C;
Ribavirin;
Peginterferon alpha
- MeSH:
Allografts;
Hepacivirus;
Hepatitis C, Chronic*;
Hepatitis, Chronic*;
Humans;
Interferons;
Kidney Transplantation*;
Kidney*;
Liver Diseases;
Prevalence;
Ribavirin;
Transplant Recipients
- From:Yeungnam University Journal of Medicine
2016;33(2):150-154
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hepatitis C virus (HCV) infection is present in a high proportion of patients with kidney transplantation. Compared with uninfected kidney transplant recipients, HCV infected kidney recipient have higher prevalence of liver disease and worse allograft survival after transplantation. Interferon monotherapy before transplantation is standard therapy for HCV-infected kidney transplant candidates. If HCV infection is discovered after transplantation, interferon monotherapy is considered due to the limited critical situation. However, in this patient, who was a kidney recipient, HCV infection was treated after kidney transplantation with peginterferon-α and rivabirin. As a result, the patient achieved sustained virologic response.
